Christoph Hallmann
Ingelheim Am Rhein, RP, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial.
Journal: The Lancet. Respiratory medicine
Published: January 31, 2018
Eosinophilia, Frequent Exacerbations, and Steroid Response in Chronic Obstructive Pulmonary Disease.
Eosinophilia, Frequent Exacerbations, and Steroid Response in Chronic Obstructive Pulmonary Disease.
Journal: American journal of respiratory and critical care medicine
Published: March 18, 2017
Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis.
Journal: The European respiratory journal
Published: July 06, 2016
Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume.
Journal: Thorax
Published: March 30, 2016
New guideline for idiopathic pulmonary fibrosis.
Journal: Lancet (London, England)
Published: February 05, 2016
Impact of tiotropium on exacerbations versus glycopyrronium and QVA149.
Journal: Expert review of respiratory medicine
Published: November 14, 2015
Tiotropium + olodaterol shows clinically meaningful improvements in quality of life.
Journal: Respiratory medicine
Published: April 15, 2015
Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.
Journal: International journal of chronic obstructive pulmonary disease
Published: February 25, 2015
Essential criteria for pharmacokinetic studies supporting bioequivalence of inhaled tiotropium bromide products.
Journal: Clinical pharmacology in drug development
Published: November 11, 2014
Thorax editorial by Jenkins and Beasley related to tiotropium respimat.
Journal: Thorax
Published: February 14, 2013
Showing 1-11 of 11
Last Updated: 09/26/2026